AVITA Medical shares the details from its earnings call for the second quarter of 2026.

Oct 12, 2026, 5:44 AM ETResultsRead the original at Benzinga

Good for RCEL

AVITA Medical's sales grew 18% from a year earlier, and it raised its 2026 sales forecast. Margins improved and losses narrowed, but the company has not yet reached its goal of generating cash by Q4 2026.

RCEL · AVITA Medical

AI read · Good for RCEL

The AI's read

The sales gains suggest more hospitals are using AVITA Medical’s wound-care products. The higher sales forecast, improved gross margin, and narrowing losses all support that reading. The company still has not reached its goal of generating cash, but it aims to do so by Q4 2026.

Get alerts for RCEL

Follow AVITA Medical (RCEL) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for RCEL

Free on the App Store and Google Play, or on the web.